1. United States of America Stocks

  2. •

    Healthcare

  3. •

    Biotechnology
eFFECTOR Therapeutics, Inc.

eFFECTOR Therapeutics, Inc.

EFTRW
eFFECTOR Therapeutics, Inc.US flagNASDAQ Capital Market
0.00
USD
-NaN
- -
2,822.00Market Cap
2020 Y
2021 Y
2022 Y
2023 Y
TTM
Revenue per Share
- -
- -
- -
- -
- -
Basic EPS, GAAP
- -
- -
- -
- -
- -
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
Dividend per Share
- -
- -
- -
- -
- -
Book Value per Share
- -
- -
- -
- -
- -
Tangible Book Value per Share
- -
- -
- -
- -
- -
Basic Weighted Avg Shares
- -
- -
- -
- -
- -
Sales/Revenue/Turnover
42
- -
- -
- -
- -
Operating Margin (%)
37.66
- -
- -
- -
- -
Depreciation Expense
- -
- -
- -
- -
- -
Net Income, GAAP
14
16
-23
-36
-35
Effective Tax Rate (%)
2.41
- -
- -
- -
- -
Profit Margin (%)
33.84
- -
- -
- -
- -
Working Capital
8
49
3
-6
1
LT Debt
7
20
- -
- -
- -
Total Equity
-132
17
4
-6
1
Return on Invested Capital (%)
- -
78.5
- -
- -
- -
Return on Capital (%)
- -
-15.64
- -
- -
- -
Return on Common Equity (%)
- -
- -
- -
- -
- -

Capital Structure

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
ST Debt
20
21
20
LT Borrowings
- -
- -
- -
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
2
3
4
Market Capitalization
- -
- -
- -

Working Capital

FRC

•

in mil. unless spec.
Sep'23
Dec'23
Mar'24
Total Current Assets
19
20
26
Cash, Cash Equivalents & STI
18
18
25
Accounts Receivable, Net
- -
- -
- -
Inventories
- -
- -
- -
Total Current Liabilities
24
26
26
Payables & Accruals
2
4
5
ST Debt
20
21
20
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
- -
-248.74%
Free Cash Flow
- -
- -
13.63%
Net Income, GAAP
- -
- -
58%
Sales/Revenue/Turnover
- -
- -
- -
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2022
- -
- -
- -
- -
- -
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -

Company Description

APIChat
CEO
Davide Ruggero
Full Time Employees
14
Sector
Healthcare
Industry
Biotechnology
Address
142 North Cedros Avenue Solana Beach DE United States of America 92075
IPO Date
Mar 1, 2021
CIK
0001828522
Website
effector.com
Similar Companies
Humacyte, Inc. (HUMAW)
Zhejiang Jolly Pharmaceutical Co.,LTD (300181.SZ)
Valerio Therapeutics S.A. (ALVIO.PA)
Cotinga Pharmaceuticals Inc. (COTQF)
Karolinska Development AB (publ) (KDEV.ST)
Nykode Therapeutics AS (NYKD.OL)
Business
eFFECTOR Therapeutics, Inc. (EFTRW) is a clinical-stage biopharmaceutical company that develops selective translation regulator inhibitors for oncology indications; tomivosertib, an oral small-molecule inhibitor of MNK1/2 evaluated in a Phase 2b trial combined with pembrolizumab for metastatic non-small cell lung cancer; zotatifin, a small-molecule inhibitor of eIF4A advanced in Phase 2a expansion cohorts for biomarker-positive solid tumors including ER+ breast cancer and KRAS-mutant NSCLC, and in an investigator-sponsored Phase 2 trial with abemaciclib and letrozole for ER+ endometrial cancer and low-grade serous ovarian cancer via collaboration with Dana-Farber Cancer Institute; plus preclinical inhibitors of eIF4E under a global research collaboration and license agreement with Pfizer Inc. that provided $15 million upfront and potential milestones up to $492 million. Founded in 2012 and formerly headquartered in Solana Beach, California, with a recent address at 124 Washington Street, Ste. 101, Foxboro, MA 02035, the company pioneered oncology therapeutics targeting the eIF4F complex to modulate mRNA translation in cancer pathways like PI3K-AKT and RAS-MEK. In June 2024, following disappointing Phase 2b results for tomivosertib in frontline NSCLC that halted its development, eFFECTOR initiated a wind-down of operations including termination of all employees, appointed liquidation specialist Craig R. Jalbert as CEO, President, Treasurer, Secretary, and sole board member, pursued strategic alternatives for its pipeline programs, voluntarily requested delisting from Nasdaq due to non-compliance, and ceased active business activities with its website confirming the company is no longer operating.